查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1840573

直接抗病毒市场（按产品类型、药物类别、分销管道和最终用户划分）—2025-2032 年全球预测

Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

直接抗病毒药物市场预计到 2032 年将成长至 339.2 亿美元，复合年增长率为 13.65%。

主要市场统计数据
基准年2024年 121.8亿美元
预计2025年 138.7亿美元
预测年份：2032年 339.2亿美元
复合年增长率（%） 13.65%

将直接抗病毒疗法的临床、操作和商业性基础具体化，以支持医疗保健相关人员的策略决策

直接抗病毒药物的出现永久重塑了我们对病毒性肝病和感染疾病的管理方法，显着改善了患者的预后，并重新定义了对根治性治疗途径的期望。本简介提供了这些治疗方法的临床和商业性背景，重点介绍了作用机制的创新、不断发展的治疗层级以及对医疗保健系统的更广泛影响。本简介也总结了近期的临床进展，其中更短的疗程、更高的耐受性和全基因型活性正在改变治疗模式，并加速了专家临床医生的采用。

从供应链角度来看，生产复杂性和原料药采购已成为开发商和采购商共同关注的关键因素。因此，品质源于设计的生产、生物製药製程控制以及策略性供应商关係对于确保可预测的产品供应正变得越来越重要。同时，付款方的观点也不断演变，更注重长期疗效和医疗成本节约，进而影响处方决策和合约签订策略。

由于诊断整合、治疗合作计划和分散护理模式将在未来塑造直接抗病毒药物的临床部署，本介绍透过概述临床疗效、营运部署、监管监督和商业性执行之间的相互关係来建构以下部分，领导者在将专案从开发推进到常规临床实践时必须协调这些关係。

临床突破、分销创新和监管调整如何融合，重新定义抗病毒疗法的治疗途径和商业策略

随着临床进展与医疗保健服务和商业策略的变化相融合，直接抗病毒药物领域正在经历加速的转型。治疗方案正从渐进式改善转变为对治癒率和治疗便利性的根本性不同预期，这促使相关人员重新评估标准治疗途径和人群层面的根除策略。同时，药理学的进展，尤其是组合方案，正在改变临床试验设计和终点选择，从而为监管核准和产品说明书扩展提供更高效的途径。

同时，分销格局也在经历结构性变革。数位医疗平台和远端医疗降低了诊断和治疗的门槛，使早期疗育成为可能，并扩大了三级医疗机构以外可治疗的患者群体。这种转变正在推动诊断开发商、专科诊所和社区医疗服务提供者之间更紧密的合作，并要求製造商采用更灵活的商业化模式，以支持不同医疗机构的教育、依从性和监测。

法律规范也进行了调整，更加重视真实世界证据和上市后监测，以监测更广泛人群的长期疗效和安全性。随着这些变革力量的持续互动，製造商、付款人和相关人员将面临机会和挑战。积极主动地将临床开发与可扩展交付模式相结合的相关人员将最有可能充分发挥下一代直接抗病毒疗法的内在价值。

评估近期贸易政策和关税发展如何改变抗病毒治疗供应链的弹性、筹资策略和采购惯例

关税征收和贸易政策调整对医药供应链、筹资策略和贸易经济（包括临床可及性和生产规划）产生了连锁反应。关税相关成本影响了活性药物原料药和辅料的采购选择，迫使製造商多元化供应商、重新定位区域生产基地并重新配置库存缓衝。这些商业应对措施不仅仅是战术性的；它们会改变产品上市前置作业时间，限制应对力，并使与大型机构和政府买家的合约谈判变得复杂。

此外，关税与监管和品质要求相互影响，使采购决策更加复杂。当受关税影响地区的供应商也拥有监管部门的核准或专业製造能力时，企业将面临成本、合规性和上市速度之间的权衡。为此，企业越来越多地寻求区域製造伙伴关係、清关安排和垂直整合，以降低此类风险。同时，采购组织和付款方正在重新评估合约结构，以防范价格波动和供应中断，并倾向于签订多年期合同，并在必要时增加库存承诺。

重要的是，关税也将再形成战略投资决策。计划扩大产能、推出新产品或拓展地域的公司必须将成本动态的变化纳入其情境规划和资本配置中。透过深思熟虑的供应链重新设计、积极与监管机构沟通以及合约创新，相关人员可以降低风险并维持患者可及性，但这些调整需要有意识的跨职能协调才能有效且可持续。

多维细分洞察揭示产品类型、治疗层级、管道和最终用户动态如何影响策略和部署

细分洞察揭示了直接抗病毒市场在关键维度上的需求驱动因素、临床特征和分销动态的差异。根据产品类型，我们分析了品牌药和学名药市场，以及这些差异如何影响定价动态、通路支援以及确保患者接受度和依从性所需的商业伙伴关係关係的性质。品牌药通常需要在教育、实证和专业分销方面进行投资，而学名药则强调成本竞争力、大规模生产和高效的通路渗透。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大全基因型直接抗病毒方案以解决丙型肝炎基因型多样性
  • 综合现实世界证据证明 DAA联合治疗的成本效益
  • 重点缩短DAA治疗时间，提高病患依从性
  • 全球儿科族群口服 DAA 疗法获得监管部门核准
  • 采用照护现场技术，即时启动直接抗病毒治疗
  • 开发下一代 NS5A 抑制剂以克服抗药性相关的 HCV 变异
  • 生技公司与世界卫生组织合作，扩大中低收入国家取得直接抗病毒药物（DAA）的机会

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 直接抗病毒药物市场（依产品类型）

  • 品牌药
  • 学名药

9. 直接抗病毒药物市场（依治疗层级）

  • 联合治疗
  • Ns5A抑制剂
  • Ns5B抑制剂
  • 蛋白酶抑制剂

10. 直接抗病毒药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章直接抗病毒药物市场（按最终用户划分）

  • 家庭医疗保健
  • 医院
  • 专科诊所

12. 直接抗病毒药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章直接抗病毒药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 直接抗病毒药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Janssen Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Cipla Limited
    • Aurobindo Pharma Limited
Product Code: MRR-032A67D91452

The Direct-acting Antiviral Drug Market is projected to grow by USD 33.92 billion at a CAGR of 13.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.18 billion
Estimated Year [2025] USD 13.87 billion
Forecast Year [2032] USD 33.92 billion
CAGR (%) 13.65%

Contextualizing the clinical, operational, and commercial foundations of direct-acting antiviral therapies to frame strategic decision-making across healthcare stakeholders

The emergence of direct-acting antiviral therapies has permanently reshaped approaches to viral hepatology and infectious disease management, driving meaningful improvements in patient outcomes and redefining the expectations of curative treatment pathways. This introduction establishes the clinical and commercial context for these therapies, focusing on mechanism-of-action innovations, evolving therapeutic classes, and the broader implications for healthcare systems. It also synthesizes recent trends in clinical development where shorter regimens, improved tolerability, and pan-genotypic activity have shifted treatment paradigms and accelerated adoption among specialist clinicians.

From a supply-chain perspective, manufacturing complexity and active pharmaceutical ingredient sourcing have become central considerations for developers and purchasers alike. As a result, quality-by-design manufacturing, biologics-inspired process controls, and strategic supplier relationships are increasingly important for ensuring predictable product availability. Simultaneously, payer perspectives have evolved to emphasize long-term outcomes and cost-of-care reductions, which in turn influence formulary decisions and contracting strategies.

Looking ahead, integration of diagnostics, linkage-to-care programs, and decentralized treatment models will continue to shape the clinical deployment of direct-acting antivirals. Therefore, this introduction frames subsequent sections by outlining the intersections between clinical efficacy, operational deployment, regulatory oversight, and commercial execution that leaders must reconcile when advancing programs from development into routine clinical practice.

How clinical breakthroughs, distribution innovations, and regulatory adaptation are converging to redefine treatment pathways and commercial strategies for antiviral therapies

Transformative shifts are accelerating across the direct-acting antiviral landscape as clinical advances converge with changes in care delivery and commercial strategy. The therapeutic narrative has transitioned from incremental improvements to fundamentally different expectations around cure rates and treatment simplicity, prompting stakeholders to reevaluate standard-of-care pathways and population-level eradication strategies. Concurrently, advances in pharmacology-particularly combination regimens that enhance potency while minimizing resistance risk-have altered clinical trial designs and endpoint selection, leading to more efficient pathways for regulatory acceptance and label expansion.

In parallel, the distribution environment is undergoing a structural evolution. Digital health platforms and telemedicine have reduced barriers to diagnosis and treatment initiation, enabling earlier intervention and expanding the pool of patients who can be treated outside tertiary centers. These shifts have fostered closer collaboration between diagnostic developers, specialty clinics, and community providers, and they have required manufacturers to adopt more flexible commercialization models that support education, adherence, and monitoring within diverse care settings.

Regulatory frameworks have also adapted, with a stronger emphasis on real-world evidence and post-marketing surveillance to monitor long-term outcomes and safety in broader populations. As these transformative forces continue to interact, they create both opportunities and complexities for manufacturers, payers, and providers; stakeholders that proactively align clinical development with scalable delivery models will be best positioned to capture the full value inherent in the next generation of direct-acting antiviral therapies.

Assessing how recent trade policy and tariff developments have reshaped supply chain resilience, sourcing strategy, and procurement practices across antiviral therapeutics

The introduction of tariffs and trade policy adjustments has a cascading effect on pharmaceutical supply chains, procurement strategies, and transactional economics that extend into clinical access and manufacturing planning. Tariff-related costs influence sourcing choices for active pharmaceutical ingredients and excipients, prompting manufacturers to reassess supplier diversification, regional production footprints, and inventory buffers. These operational responses are not merely tactical; they alter lead times for product launch, constrain responsiveness to demand surges, and increase the complexity of contract negotiations with large institutional purchasers and government buyers.

Moreover, tariffs interact with regulatory and quality requirements in ways that complicate sourcing decisions. When suppliers in tariff-impacted jurisdictions also possess regulatory approvals or specialized manufacturing capabilities, firms face trade-offs between cost, compliance, and speed to market. In response, companies increasingly explore regional manufacturing partnerships, tolling arrangements, and vertical integration to mitigate exposure. At the same time, procurement organizations and payers are re-evaluating contracting structures to protect against price volatility and supply disruptions, favoring multi-year agreements or increased inventory commitments when necessary.

Importantly, tariffs also reshape strategic investment decisions. Firms planning capacity expansions, new product rollouts, or geographic entry must incorporate the altered cost dynamics into scenario planning and capital allocation. Through careful supply-chain redesign, proactive regulatory engagement, and contractual innovation, stakeholders can reduce exposure and preserve patient access, although these adjustments require deliberate cross-functional alignment to implement effectively and sustainably.

Multidimensional segmentation insights that illuminate how product type, therapeutic class, channels, and end-user dynamics uniquely influence strategy and deployment

Segmentation insight reveals how demand drivers, clinical profiles, and distribution dynamics differ across key dimensions of the direct-acting antiviral space. Based on Product Type, market is studied across Branded Drugs and Generic Drugs, and this distinction influences pricing dynamics, channel support, and the nature of commercial partnerships required to ensure uptake and adherence. Branded products often require heavier investments in education, real-world evidence generation, and specialty distribution, while Generic Drugs emphasize cost competitiveness, scale manufacturing, and efficient channel penetration.

Based on Therapeutic Class, market is studied across Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor, and Protease Inhibitor, and each class carries unique clinical positioning, resistance considerations, and regimen complexity that shape prescribing patterns. Combination Therapy often addresses multi-genotype coverage and resistance suppression, whereas class-specific agents may be prioritized where monotherapy still offers clinical advantage or where tolerability is paramount. This therapeutic segmentation has direct consequences for clinical trial design, labeling strategies, and post-approval lifecycle management.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which affects how products are accessed, how adherence is monitored, and how patient support programs are deployed. Hospital Pharmacy channels typically handle more complex cases and institutional contracting, while Online Pharmacy platforms enable broader patient reach and convenience. Based on End User, market is studied across Home Healthcare, Hospitals, and Specialty Clinics, and the end-user mix shapes training requirements, monitoring protocols, and the design of ancillary services required to ensure optimal outcomes. Taken together, these segmentation lenses provide a multidimensional view that informs product positioning, commercialization tactics, and partnership priorities.

Comparative regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that drive differentiated access and deployment approaches

Regional dynamics have become a decisive factor in shaping development priorities, regulatory engagement strategies, and commercialization planning for direct-acting antivirals. In the Americas, payer-driven contracting, outcomes-based agreements, and robust specialty care networks influence how manufacturers approach formulary access and patient support programs. Regulatory agencies and public health initiatives often prioritize elimination goals, which creates collaborative opportunities between manufacturers and public-sector purchasers to align supply and demand for high-impact interventions.

In Europe, Middle East & Africa, healthcare systems exhibit a breadth of procurement models and budgetary constraints that require nuanced market access strategies. Countries with centralized healthcare procurement may favor negotiated pricing and volume guarantees, whereas regions with heterogeneous payers necessitate adaptable contracting and evidence generation to meet divergent reimbursement thresholds. Meanwhile, supply-chain complexity and capacity variability across parts of Europe, the Middle East, and Africa underscore the need for regional manufacturing partnerships and tailored distribution solutions.

In Asia-Pacific, rapid scale-up of diagnostic and treatment programs, coupled with strong manufacturing capabilities in several countries, creates both competitive and collaborative opportunities. Diverse regulatory pathways and varying degrees of local production capacity make it critical to align product registrations, technology transfers, and commercial launches with country-specific requirements. Across all regions, successful strategies will integrate local clinical engagement, regionally appropriate pricing models, and resilient distribution networks to ensure broad and equitable access to antiviral therapies.

Corporate positioning and competitive dynamics driven by innovation leadership, manufacturing scale, and strategic partnerships that determine sustainable advantage in antiviral therapeutics

Company-level dynamics reflect a mix of innovation leadership, manufacturing scale, and strategic collaborations that collectively determine competitive positioning within the direct-acting antiviral space. Innovative pharmaceutical and biotech companies focus on advancing mechanism-of-action differentiation, expanding pan-genotypic indications, and generating robust safety and real-world effectiveness evidence to sustain clinical preference. These organizations typically invest in integrated ecosystem capabilities-combining clinical affairs, pharmacovigilance, and digital adherence tools-to support durable market access and physician confidence.

Meanwhile, manufacturers with strong generic capabilities emphasize operational excellence, cost optimization, and rapid scale-up to meet demand in price-sensitive markets. Contract manufacturing organizations and tolling partners play a pivotal role in enabling agility, allowing brand and generic players to adjust output in response to procurement cycles and supply shocks. Partnership strategies, including licensing agreements, co-promotion deals, and public-private collaborations, continue to shape the competitive landscape and accelerate treatment uptake in public health initiatives.

Across the corporate landscape, mid-size specialty companies and larger pharma firms differentiate through strategic investments in diagnostics integration, patient support programs, and targeted distribution partnerships. Leadership teams that align clinical differentiation with pragmatic commercialization models and resilient manufacturing networks will be better equipped to navigate regulatory complexity and sustain long-term value creation in this therapeutic area.

Practical strategic actions for industry leaders to align clinical evidence, supply-chain resilience, and channel-specific commercialization to accelerate access and sustain value

Leaders seeking to capitalize on the evolving direct-acting antiviral landscape should adopt a set of pragmatic, high-impact actions that balance clinical credibility with operational resilience. First, integrate clinical development and commercialization planning early so that trial designs generate evidence relevant to payers, guideline committees, and real-world practice. By aligning endpoints, patient populations, and health-economic evidence needs from the outset, organizations can shorten the pathway from approval to meaningful uptake.

Second, strengthen supply-chain resilience through supplier diversification, selective regional manufacturing partnerships, and flexible contract manufacturing arrangements. Scenario planning that incorporates potential trade-policy shifts, raw-material constraints, and demand volatility will enable more adaptive sourcing decisions. Third, tailor distribution and patient-support models to channel realities: design differentiated approaches for Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy that reflect variations in access, adherence, and monitoring requirements. Complement these channel strategies with robust diagnostic linkages and provider education initiatives to ensure appropriate patient selection and follow-through.

Finally, pursue collaborative pricing and contracting approaches with payers, including outcomes-based agreements where appropriate, and invest in data infrastructure to demonstrate value in routine practice. By combining these actions-evidence-aligned development, supply-chain robustness, channel-specific commercialization, and payer collaboration-industry leaders can enhance access, reduce variability in outcomes, and create defensible commercial positions.

A reproducible mixed-methods research design combining primary expert interviews, literature synthesis, supply-chain mapping, and scenario stress testing to ensure robust insights

This research employed a mixed-methods approach that integrates primary qualitative interviews, secondary literature synthesis, and supply-chain and regulatory analysis to produce a comprehensive view of the direct-acting antiviral environment. Primary insights were derived from structured interviews with experienced clinicians, formulary decision-makers, procurement specialists, and industry executives, enabling triangulation of clinical practice patterns, contracting dynamics, and operational challenges. Secondary analysis synthesized peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial outcomes to contextualize therapeutic efficacy, safety profiles, and regulatory trends.

In addition, supply-chain mapping and policy analysis were used to assess sourcing risks, manufacturing dependencies, and the implications of trade-policy shifts. Scenario-based stress testing helped illuminate how different tariff and procurement outcomes could affect operational decisions and stakeholder incentives. Evidence quality checks and cross-validation between internal sources and external subject-matter experts were implemented to ensure the robustness of conclusions.

Transparency in methodology supports reproducibility and allows stakeholders to appraise the fit of insights to their specific contexts. Where appropriate, the research highlights data limitations and recommends areas for targeted follow-up research or bespoke analysis to address organization-specific questions related to access, pricing strategies, and manufacturing expansion planning.

Synthesis of strategic imperatives emphasizing alignment between clinical innovation, operational resilience, and collaborative access models to secure sustainable therapeutic impact

This final synthesis reiterates the central themes that should guide executive decision-making in the direct-acting antiviral domain: therapeutic innovation must be matched with pragmatic strategies for access, delivery, and supply assurance. Clinical advances have created opportunities to rethink treatment pathways and public-health approaches, but capturing the benefits requires careful coordination across development, manufacturing, and market-access functions. Operational resilience-particularly around supplier diversification and manufacturing flexibility-remains essential to protecting product availability and upholding public-health commitments.

Moreover, segmentation and regional nuance matter. Decisions about product type, therapeutic class, distribution channel, and end-user settings will determine the traction a therapy achieves in different healthcare systems and will inform the investments needed across evidence generation, education, and logistics. Finally, collaborative arrangements-whether with payers, public-health agencies, or manufacturing partners-can accelerate access while sharing risk and aligning incentives around long-term outcomes. As organizations translate these conclusions into operational plans, they should prioritize alignment between clinical objectives and commercial realities, ensuring that strategy execution remains patient-centered and resilience-focused.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding pan-genotypic direct-acting antiviral regimens addressing hepatitis C genotype diversity
  • 5.2. Integration of real-world evidence demonstrating cost-effectiveness of combination DAA therapies
  • 5.3. Increasing emphasis on shortened DAA treatment durations to improve patient adherence rates
  • 5.4. Regulatory approvals for all-oral DAA therapies in paediatric patient populations worldwide
  • 5.5. Adoption of point-of-care diagnostics to enable immediate linkage to direct-acting antiviral treatment
  • 5.6. Development of next-generation NS5A inhibitors to overcome resistance-associated HCV variants
  • 5.7. Collaborations between biotech firms and global health agencies to expand DAA access in LMICs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Direct-acting Antiviral Drug Market, by Product Type

  • 8.1. Branded Drugs
  • 8.2. Generic Drugs

9. Direct-acting Antiviral Drug Market, by Therapeutic Class

  • 9.1. Combination Therapy
  • 9.2. Ns5A Inhibitor
  • 9.3. Ns5B Inhibitor
  • 9.4. Protease Inhibitor

10. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Direct-acting Antiviral Drug Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Direct-acting Antiviral Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Direct-acting Antiviral Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Direct-acting Antiviral Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Gilead Sciences, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Janssen Pharmaceuticals, Inc.
    • 15.3.5. Bristol-Myers Squibb Company
    • 15.3.6. Roche Holding AG
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
    • 15.3.8. Mylan N.V.
    • 15.3.9. Cipla Limited
    • 15.3.10. Aurobindo Pharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

TABLE 3